Navigation Links
Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
Date:2/9/2009

, PRO 2000 had undergone extensive safety testing in several clinical trials involving women and men in the United States, Europe, Africa and India.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA XR(TM), NEBIDO(R) , VANTAS(R) and SUPPRELIN(R) LA; need for additional funds and corporate partners, including for the development of our products; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR(TM); reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL(R) and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the R
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering
2. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
3. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
4. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
5. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
6. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
7. Indevus Announces Submission of New Drug Application
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
10. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
11. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Egalet Corporation (Nasdaq: EGLT ) ... on developing, manufacturing and marketing innovative pain treatments, ... underwritten public offering of 7,666,667 shares of its ... $11.25 per share. The shares of common stock ... the exercise in full by the underwriters of ...
(Date:7/31/2015)... 31, 2015 Magnaquest, a ... data and cloud computing operators has signed a ... giant for Internet of Things (IoT) related initiative. ... on subscription model.      (Logo: ... striving for business innovations to make healthcare services ...
(Date:7/30/2015)... (NYSE: RMD ) today announced results for its ... was $453.1 million, a 9 percent increase compared with ... increase on a constant currency basis).  Net income was ... 2014.  Diluted earnings per share for the quarter were ... The results for the quarter ended ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... 17, 2011 Reportlinker.com announces that a ... its catalogue: Product ... Pipeline Strengthening the In-Vitro Diagnostics and Cardiovascular ... http://www.reportlinker.com/p0397058/Product-Pipeline-in-Medical-Equipment-Market---Robust-Pipeline-Strengthening-the-In-Vitro-Diagnostics-and-Cardiovascular-Devices-Market.html Product Pipeline in ...
... Reportlinker.com announces that a new market research report is ... U.S. Medical Laboratories Industry - 10th Edition ... Marketdata study is a comprehensive analysis of the fragmented ... The industry was hurt by the recession but is ...
Cached Medicine Technology:Reportlinker Adds Product Pipeline in Medical Equipment Market - Robust Pipeline Strengthening the In-Vitro Diagnostics and Cardiovascular Devices Market 2Reportlinker Adds The U.S. Medical Laboratories Industry - 10th Edition 2
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe Organic ... very first small business donation to kick off the campaign for healing and Well-Being. ... legacy includes a complete line of raw, organic hair care products, as well as ...
(Date:7/31/2015)... , ... July 31, 2015 , ... When the weather ... Super-Sod debuted their new type of sod called Leisure Time(TM) zoysia . It's ... process. , To commemorate introduction of this new type of sod, Super-Sod is giving ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted by Becker’s ... predictive health analytics , Jvion continues to disrupt the predictive analytic and big ... targets patient and population level illness to drive prevention and better health outcomes. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Jacksonville-based ... its new True North Conference Center. The medical community, social workers, law enforcement, ... may be more aligned in the effort to better understand and combat sex ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to the article published July 27 ... Pasadena courthouse was contained and extinguished by the city’s fire department before it caused major ... at the time of the fire, and it was a fire alarm system that tipped ...
Breaking Medicine News(10 mins):Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3
... Researchers from the University of Michigan Comprehensive Cancer Center have identified a panel of small molecules, or ... , Click here for more information. , ... , , , , ... , , , , ...
... in the arteries of the brain using angioplasty to widen ... open. However, in-stent stenosis, or a re-blockage of the artery ... is estimated to occur in up to 30 percent of ... new study by researchers at Rush University Medical Center has ...
... 2009 issue of the Journal of the American ... improve memory and lead to faster thinking. , ... on cognitive tests after repeatedly practicing those tests, but ... commercially available software program to improvement on unaffiliated standard ...
... Generation-X say they feel unprepared for long-term care and ... to prepare for their futures, according to a survey ... survey, conducted by StrategyOne on behalf of AHIP, found ... 1960 and 1980 feel somewhat or entirely unprepared for ...
... DES MOINES, Iowa, Feb. 11 Protocol ... Steps online action plans with two additions: diabetes prevention ... health-improvement platform, these action plans help promote wellness through ... ConXus Steps library, each new action plan comprises:, ...
... LEADING CANCER RESEARCHER TO OFFER POLICIES TO COMBAT DISEASE, ... Mendelsohn, president of The University of Texas ... for advancing the fight against cancer at a National ... Feb. 17, in the Lisagor Room, 13th floor, 529 ...
Cached Medicine News:Health News:Researchers discover metabolite linked to aggressive prostate cancer 2Health News:Researchers discover metabolite linked to aggressive prostate cancer 3Health News:Researchers discover metabolite linked to aggressive prostate cancer 4Health News:Noninvasive screening test may detect narrowing in intracranial stents 2Health News:Computer exercises improve memory and attention 2Health News:Generation-X Feels Unprepared for Long-Term Care Costs and the Future, Survey Finds 2Health News:Generation-X Feels Unprepared for Long-Term Care Costs and the Future, Survey Finds 3Health News:PDHI Adds Diabetes and Heart Disease Prevention to ConXus Steps Library of Action Plans 2Health News:PDHI Adds Diabetes and Heart Disease Prevention to ConXus Steps Library of Action Plans 3Health News:National Press Club to Host 'NEWSMAKER' Media Briefing on Health Policy Recommendations With Dr. John Mendelsohn 2
Enzyme Immunoassay of Protein C Antigenby ELISA Method, 96 tests...
... Colorimetric Assay of ... and Low Molecular ... substrate CBS 31.39, ... purified bovine ATIII, ...
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor V Assay by STA© Analyzers. Freeze-dried human plasma, artificially depleted of factor V....
Medicine Products: